In this study, we conducted both VSX1 variant screening and clinical examinations of families affected by KC to explore the potential of molecular screening as an approach to detecting subclinical or suspected KC at an extremely early stage before the emergence of clinical signs. This evidence concerns the gene VSX1 and keratoconus.